These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1081 related articles for article (PubMed ID: 3018223)

  • 1. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Castration blocks chronic sulpiride-induced desensitization of striatal D1 receptor-stimulated adenylate cyclase activity in male rats.
    Ryan-Jastrow T; Gnegy ME
    J Pharmacol Exp Ther; 1989 Feb; 248(2):626-31. PubMed ID: 2521900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
    Sesack SR; Bunney BS
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
    Roseboom PH; Gnegy ME
    Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippocampal modulation of locomotor activity induced by focal activation of postsynaptic dopamine receptors in the core of the nucleus accumbens.
    Rouillon C; Abraini JH; David HN
    Hippocampus; 2007; 17(11):1028-36. PubMed ID: 17604350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain.
    Undie AS; Friedman E
    J Pharmacol Exp Ther; 1990 Jun; 253(3):987-92. PubMed ID: 1972756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.
    Moro H; Sato H; Ida I; Oshima A; Sakurai N; Shihara N; Horikawa Y; Mikuni M
    Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
    Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
    J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway.
    Santanavanich C; Ebadi M; Govitrapong P
    J Pineal Res; 2005 Apr; 38(3):170-5. PubMed ID: 15725338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limbic pallidal adaptations following long-term cessation of dopaminergic transmission: lack of upregulation of dopamine receptor function.
    Heidenreich BA; Mitrovic I; Battaglia G; Napier TC
    Exp Neurol; 2004 Apr; 186(2):145-57. PubMed ID: 15026253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
    Clark D; White FJ
    Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
    Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
    J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats.
    Neisewander JL; Lucki I; McGonigle P
    J Pharmacol Exp Ther; 1991 May; 257(2):850-60. PubMed ID: 2033524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.